{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T12:38:28Z","timestamp":1722083908907},"reference-count":30,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2009.0843","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:12:39Z","timestamp":1525252359000},"source":"Crossref","is-referenced-by-count":6,"title":["Colorectal Carcinoma"],"prefix":"10.3238","author":[{"given":"Wolff","family":"Schmiegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Porschen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Reinacher-Schick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2009,12,21]]},"reference":[{"key":"10.3238\/arztebl.2009.0843_ref1","unstructured":"Robert Koch-Institut. Krebs in Deutschland 2008.http:\/\/www.rki.de"},{"key":"10.3238\/arztebl.2009.0843_ref2","doi-asserted-by":"crossref","unstructured":"Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 627\u201337.","DOI":"10.7326\/0003-4819-149-9-200811040-00243"},{"key":"10.3238\/arztebl.2009.0843_ref3","doi-asserted-by":"crossref","unstructured":"Schmiegel W, Reinacher-Schick A, Arnold D, et al.: S3-Leitlinie \u201eKolorektales Karzinom\u201c \u2013 Aktualisierung 2008. Z Gastroenterol 2008; 46: 799\u2013840.","DOI":"10.1055\/s-2008-1027726"},{"key":"10.3238\/arztebl.2009.0843_ref4","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nhofer B, Kuhlen R, Neumann P, et al.: Clinical practice guideline: non-invasive mechanical ventilation as treatment of acute respiratory failure [Klinische Leitlinie. Nicht invasive Beatmung bei respiratorischer Insuffizienz]. Dtsch Arztebl Int 2008; 105(24): 424\u201333.","DOI":"10.3238\/arztebl.2008.0424"},{"key":"10.3238\/arztebl.2009.0843_ref5","doi-asserted-by":"crossref","unstructured":"Winawer SJ, Zauber AG, Ho MN, et al.: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977\u201381.","DOI":"10.1056\/NEJM199312303292701"},{"key":"10.3238\/arztebl.2009.0843_ref6","doi-asserted-by":"crossref","unstructured":"Martinez ME, Baron JA, Lieberman DA, et al.: A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009; 136: 832\u201341.","DOI":"10.1053\/j.gastro.2008.12.007"},{"key":"10.3238\/arztebl.2009.0843_ref7","doi-asserted-by":"crossref","unstructured":"Brenner H, Hoffmeister M, Stegmaier C, et al.: Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies. Gut 2007; 56: 1585\u20139.","DOI":"10.1136\/gut.2007.122739"},{"key":"10.3238\/arztebl.2009.0843_ref8","doi-asserted-by":"crossref","unstructured":"Lieberman DA, Weiss DG, Harford WV, et al.: Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007; 133: 1077\u201385.","DOI":"10.1053\/j.gastro.2007.07.006"},{"key":"10.3238\/arztebl.2009.0843_ref9","doi-asserted-by":"crossref","unstructured":"Higaki S, Hashimoto S, Harada K, et al.: Long-term follow-up of large flat colorectal tumors resected endoscopically. Endoscopy 2003; 35: 845\u20139.","DOI":"10.1055\/s-2003-42622"},{"key":"10.3238\/arztebl.2009.0843_ref10","doi-asserted-by":"crossref","unstructured":"Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113\u201330.","DOI":"10.1111\/j.1365-2559.2006.02549.x"},{"key":"10.3238\/arztebl.2009.0843_ref11","doi-asserted-by":"crossref","unstructured":"Ernst A, Eberhardt R, Wahidi M, Becker HD, Herth FJ: Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006; 129: 734\u20137.","DOI":"10.1378\/chest.129.3.734"},{"key":"10.3238\/arztebl.2009.0843_ref12","doi-asserted-by":"crossref","unstructured":"Yousfi M, Gostout CJ, Baron TH, et al.: Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004; 99: 1785\u20139.","DOI":"10.1111\/j.1572-0241.2004.30368.x"},{"key":"10.3238\/arztebl.2009.0843_ref13","doi-asserted-by":"crossref","unstructured":"Deinlein P, Reulbach U, Stolte M, Vieth M: Risikofaktoren der lymphogenen Metastasierung von kolorektalen pT1-Karzinomen. Pathologe 2003; 24: 387\u201393.","DOI":"10.1007\/s00292-003-0632-y"},{"key":"10.3238\/arztebl.2009.0843_ref14","doi-asserted-by":"crossref","unstructured":"O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420ff.","DOI":"10.1093\/jnci\/djh275"},{"key":"10.3238\/arztebl.2009.0843_ref15","doi-asserted-by":"crossref","unstructured":"Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-6.","DOI":"10.7326\/0003-4819-122-5-199503010-00001"},{"key":"10.3238\/arztebl.2009.0843_ref16","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109\u201316.","DOI":"10.1200\/JCO.2008.20.6771"},{"key":"10.3238\/arztebl.2009.0843_ref17","doi-asserted-by":"crossref","unstructured":"Twelves C, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696\u2013704.","DOI":"10.1056\/NEJMoa043116"},{"key":"10.3238\/arztebl.2009.0843_ref18","doi-asserted-by":"crossref","unstructured":"Quasar Collaborative Group Gray R, Barnwell J, Mc Conkey C, et al.: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020\u20139.","DOI":"10.1016\/S0140-6736(07)61866-2"},{"key":"10.3238\/arztebl.2009.0843_ref19","doi-asserted-by":"crossref","unstructured":"Sargent DJ, Goldberg RM, Jacobson SO, et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091\u20137.","DOI":"10.1056\/NEJMoa010957"},{"key":"10.3238\/arztebl.2009.0843_ref20","doi-asserted-by":"crossref","unstructured":"Sauer R, Becker H, Hohenberger W, et al.: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731\u201340.","DOI":"10.1056\/NEJMoa040694"},{"key":"10.3238\/arztebl.2009.0843_ref21","doi-asserted-by":"crossref","unstructured":"Mitry E, Fields AL, Bleiberg H, et al.: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906\u201311.","DOI":"10.1200\/JCO.2008.17.3781"},{"key":"10.3238\/arztebl.2009.0843_ref22","doi-asserted-by":"crossref","unstructured":"Nordlinger B, Sorbye H, Glimelinus B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40 983): a randomised controlled trial. Lancet 2008; 371: 1007\u201316.","DOI":"10.1016\/S0140-6736(08)60455-9"},{"key":"10.3238\/arztebl.2009.0843_ref23","doi-asserted-by":"crossref","unstructured":"Tournigand C, Cervantes A, Figer A, et al.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer\u2014a GERCOR study. J Clin Oncol 2006; 24: 394\u2013400.","DOI":"10.1200\/JCO.2005.03.0106"},{"key":"10.3238\/arztebl.2009.0843_ref24","doi-asserted-by":"crossref","unstructured":"Koopman M, Antonini NF, Douma J, et al.: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135\u201342.","DOI":"10.1016\/S0140-6736(07)61086-1"},{"key":"10.3238\/arztebl.2009.0843_ref25","doi-asserted-by":"crossref","unstructured":"Seymour MT, Maughan TS, Ledermann JA, et al.: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143\u201352.","DOI":"10.1016\/S0140-6736(07)61087-3"},{"key":"10.3238\/arztebl.2009.0843_ref26","doi-asserted-by":"crossref","unstructured":"Allegra CJ, Yothers G, O'Connell MJ, et al.: Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385\u201390.","DOI":"10.1200\/JCO.2009.21.9220"},{"key":"10.3238\/arztebl.2009.0843_ref27","doi-asserted-by":"crossref","unstructured":"Jackson McCleary NA, Meyerhardt J, Green E, et al.: Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II\/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 2009; 27: p15 (suppl; abstr 4010).","DOI":"10.1200\/jco.2009.27.15_suppl.4010"},{"key":"10.3238\/arztebl.2009.0843_ref28","doi-asserted-by":"crossref","unstructured":"Falcone A, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670\u20136 (EBM-Grad: I b).","DOI":"10.1200\/JCO.2006.09.0928"},{"key":"10.3238\/arztebl.2009.0843_ref29","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. NEJM 2009; 360: 1408\u201317.","DOI":"10.1056\/NEJMoa0805019"},{"key":"10.3238\/arztebl.2009.0843_ref30","doi-asserted-by":"crossref","unstructured":"Saltz LB, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013\u20139.","DOI":"10.1200\/JCO.2007.14.9930"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T09:53:29Z","timestamp":1638870809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2009.0843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2009.0843","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,21]]}}}